H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Get your full text copy in PDF

Modafinil for narcolepsy: Systematic review and meta-analysis

Dominik Golicki, Malgorzata M. Bala, Maciej Niewada, Aleksandra Wierzbicka

Med Sci Monit 2010; 16(8): RA177-186

ID: 881094


Background:    To assess the effectiveness and safety of modafinil vs. no active treatment or other drugs in the treatment of narcolepsy.
    Material/Methods:    The following electronic databases were searched throughout January 2009: MEDLINE, EMBASE and The Cochrane Library. Additional references were obtained from reviewed articles. Only randomized controlled trials were included.
    Results:    We included 9 trials involving 1,054 patients in the study. Modafinil in comparison with placebo brings significant benefit in terms of elimination of excessive daytime sleepiness assessed by: ESS scale – weighted mean difference (WMD) –2.73 points (95%CI –3.39, –2.08), MSLT test – WMD 1.11 minutes (95%CI 0.55, 1.66) and MWT test – WMD 2.82 minutes (95%CI 2.40, 3.24), as well as the number and duration of somnolence, sleep attacks and naps per day, but was not different from placebo in the number of attacks of cataplexy per day. Modafinil in comparison with placebo improved quality of life of narcoleptic patients according to SF-36 questionnaire, but was associated with more common nausea. It had similar effect on excessive daytime sleepiness as sodium oxybate and was associated with less common nausea.
    Conclusions:    In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree